ArticleScientific reports2026
Hybrid tuned deep learning model for breast cancer diagnosis using genetic data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The early diagnosis and prognosis of breast cancer is essential for improving breast cancer survival rates and improving breast cancer clinical outcomes. This study aims to provide breast cancer predictive capabilities through the development and application of a robust hybrid computational prediction methodology that performs testing across multiple whole-genome studies; this research was validated using both TCGA (The Cancer Genome Atlas) and METABRIC (Molecular Taxonomy of Breast Cancer International Consortium). Instead of using traditional methods, where researchers select specific gene sets from the literature, we chose to operate on the highest dimensional input (17,814 genes in TCGA) and the most extensive set of clinical and genomic variables available (503 clinical/genomic features in METABRIC). A multi-stage feature selection process utilizing Random Forest (RF) rankings in conjunction with Association Rule Mining (ARM) was developed to discover important biomarkers. Predictive analysis was performed using a hybrid deep learning model, which contains Convolutional Neural Networks (CNN) in combination with Bidirectional Long Short-Term Memory (BiLSTM) networks, with iterative optimization through the utilization of Bayesian methods. SMOTE and Gaussian noise augmentations were incorporated into the new model to provide additional robustness by addressing class imbalance and minimizing the risk of overfitting (due to the amount of noise present in the training data). The new model outperformed the TCGA-derived model with an accuracy of 97.4% (AUC=0.995), and after validation on the METABRIC dataset, exhibited an even greater accuracy of 99.30% with a 100% recall rate for predicting cancer-related mortality. Through these findings, we have shown that the integration of association-based feature selection with hybrid deep learning architectures has created a tool for breast cancer diagnosis and prognosis that can provide reliable and generalizable results for diverse groups of patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.